Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its ...

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating reaffirmed by Needham & Company LLC in a report released on Friday,Benzinga reports. A number of other research ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) gapped up prior to trading on Friday after Scotiabank raised their price target on the stock from $430.00 to $433.00. The stock had ...

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...

Fintel reports that on January 30, 2025, Wells Fargo downgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day.